What is Immuno Oncology Assays Market?
Over the past decade, immuno-oncology (IO) has appeared as a novel and powerful approach to cancer treatment through the stimulation of the bodyís own immune system to kill cancer cells. This newly approved method of treating cancer is rapidly developing, with many accelerated permissions by the US Food and Drug Administration and European Medicines Agency in 2019. Immuno-oncology is an area of scientific research included in investigating how the immune system can fight cancers. It is a method used to find out the potential of the immune system to fight against cancer cells. Further, cancer has become one of the most frequent causes of mortality in western industrialized countries. Immune oncological approaches are serving to determine new potent curative cancer treatment that could possibly even lead to the eradication of most types of cancer.
The market study is being classified, by Application (Research Applications and Clinical Diagnostics) and major geographies with country level break-up.
Thermo Fischer Scientific (United States), Roche Diagnostics (Switzerland), Agilent Technologies (United States), Illumina (United States), F. Hoffmann-La Roche Ltd (Switzerland), HTG Molecular Diagnostics, Inc. (United States), Illumina, Inc.(United States), Merck KGaA (United State), PerkinElmer Inc. (United States) and Qiagen (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Sartorius AG (Germany) and NanoString Technologies, Inc. (United States).
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Immuno Oncology Assays market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Immuno Oncology Assays market by Type, Application and Region.
On the basis of geography, the market of Immuno Oncology Assays has been segmented into . Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Rise in cancer incidence across the globe and increase in R&D activities for the developing cancer treatment
- Rising Incidence of Cancer and Increasing Adoption of Targeted Therapy
- A cancer diagnosis is increasing the need for the reagent and antibodies increases, thus propelling the segment growth.
- Increased focus on developing automated immuno-oncology assay is anticipated to create lucrative opportunities in the near future.
- Unfavourable Regulatory and Reimbursement Scenario
- Increasing use of Immuno Oncology Assays in cancer treatment as Immunotherapy is used to fight off diseases such as cancer by stimulating or boosting the patients own immune system or giving man-made immune system proteins to attack cancer cells.
- High Amount of Capital Investments and Low Benefit-Cost Ratio
In March 2020 Gilad acquired an immune-oncology company for USD 4.9Billion. The acquisition will give Gilead access to Forty-Sevenís investigational lead product candidate, magrolimab, a monoclonal antibody in clinical development for the treatment of numerous cancers, including myelodysplastic syndrome, acute myeloid leukaemia, and diffuse large B-cell lymphoma, the press release said.
Key Target AudienceNew Entrants/Investors, Analysts and Strategic Business Planners, Immuno Oncology Assays Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase